SCHEMBL6357003

SCHEMBL6357003

CC(C)[C@@H]1SC=CN([C@@H](Cc2ccccc2)C(=O)O)C1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
POLB P06746 3/20 0.46
HSD17B10 Q99714 2/20 0.46
KMT2A Q03164 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
PTPN7 P35236 1/20 0.46
RECQL P46063 1/20 0.46
BLM P54132 1/20 0.46
ALDH1A1 P00352 4/20 0.45
PKM P14618 1/20 0.45
GAA P10253 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44
AADAT Q8N5Z0 1/20 0.41
LMNA P02545 2/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6356999 1.00 MAPT (0.46) MAPTL3MBTL1POLBHSD17B10KMT2A
SCHEMBL6347832 0.84 MME (0.33) MAPTPOLBKMT2AMEN1
SCHEMBL6347829 0.84 MME (0.33) MAPTPOLBKMT2AMEN1
SCHEMBL6349228 0.84 MEN1 (0.39) MAPTL3MBTL1POLBHSD17B10KMT2A
SCHEMBL6348125 0.82 MEN1 (0.39) MAPTHSD17B10KMT2ATDP1MEN1
SCHEMBL6348128 0.82 MEN1 (0.39) MAPTHSD17B10KMT2ATDP1MEN1
SCHEMBL6356592 0.80 MEN1 (0.35) MAPTKMT2ATDP1MEN1LMNA
SCHEMBL6347587 0.79 MME (0.40) MAPTHSD17B10KMT2ATDP1MEN1
SCHEMBL6347591 0.79 MME (0.40) MAPTHSD17B10KMT2ATDP1MEN1
SCHEMBL6348500 0.78 ALDH1A1 (0.33) KMT2AKDM4EMEN1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 MAPT 4491/4885L3MBTL1 3961/4885POLB 3917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.